FGFR (Fibroblast growth factor receptors) are the receptors that bind to members of the fibroblast growth factor family of proteins.Pathological conditions involve some of these receptors. Achondroplasia can be brought on by a point mutation in FGFR3. Vertebrates have been found to contain five distinct membrane FGFRs, all of which are members of the tyrosine kinase superfamily (FGFR1, FGFR2, FGFR3, FGFR4, FGFR6). One of the most significant families of paracrine factors that function in the development process is the fibroblast growth factor family. They control which cells differentiate into mesoderm, the production of blood vessels, the growth of limbs, and the growth and differentiation of many different cell types.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V1998 | Formononetin (Biochanin B) | 485-72-3 | Formononetin (Biochanin B; Flavosil; Formononetol), an O-methylated isoflavone, is a naturally occuring and bioactive flavonoid found in the root of Astragalus membranaceus. |
|
V77002 | Formononetin-d3-1 (formononetin-d3) | Formononetin-d3-1 is deuterated Formononetin. | |
|
V4847 | Futibatinib (TAS-120) | 1448169-71-8 | Futibatinib (formerly also known as TAS 120; TAS-120) is a novel, potent,irreversible and orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential anticancer activity. |
|
V10988 | Gambogenic Acid | 173932-75-7 | Gambogenic Acid, a naturally occuring ingredient dound in gamboge, is a potent inhibitor of the fibroblast growth factor receptor (FGFR) signaling pathway in erlotinib-resistant non-small-cell lung cancer (NSCLC). |
|
V69449 | Gunagratinib (ICP-192) | 2211082-53-8 | Gunagratinib (ICP-192) is a low-toxic, orally bioactive pan-FGFR (fibroblast growth factor receptor) inhibitor that potently, selectively and irreversibly inhibits FGFR activity through covalent binding. |
|
V3131 | H3B-6527 | 1702259-66-2 | H3B-6527 is a potent, highly selective, orally bioavailable, covalent FGFR4 inhibitor with IC50 value of ~1.2 nM. |
|
V0614 | Infigratinib (BGJ-398; NVP-BG-J398) | 872511-34-7 | Infigratinib (also known as BGJ398; BGJ-398;NVP-BGJ398; Truseltiq) is a novel, potent, selective, andorally bioavailable FGFR (fibroblast growth factor receptors) inhibitor with potential antiangiogenic and antineoplastic activities. |
|
V4255 | Infigratinib phosphate | 1310746-10-1 | Infigratinib phosphate (formerly BGJ-398; BGJ398;NVP-BGJ398 phosphate; Truseltiq), thephosphatesalt of Infigratinib, is an orally bioavailable FGFR (fibroblast growth factor receptors) inhibitor that has gained FDA approval in May 2021 totreat cholangiocarcinoma whose disease meets certain criteria. |
|
V69450 | Irpagratinib (ABSK011) | 2230974-62-4 | Irpagratinib (ABSK011) is an orally bioactive fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor targeting FGFR4 (IC50<10 nM). |
|
V2672 | JNJ-42756493 (Erdafitinib) | 1346242-81-6 | Erdafitinib (formerly known as JNJ-42756493; JNJ42756493;Balversa), a quinoxaline derivative compound and approved anticancer drug,is a novel, potent and selective, orally bioavailable, pan inhibitor of fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. |
|
V69474 | LC-MB12 | 2828438-38-4 | LC-MB12 is an orally bioactive PROTAC compound that targets FGFR2 degradation with DC50 of 11.8 nM. |
|
V76828 | Lenvatinib-d4 (E7080-d4) | Lenvatinib-d4 is the deuterated form of Lenvatinib. | |
|
V80557 | Lenvatinib-d5 (E7080-d5) | Lenvatinib-d5 is the deuterated form of Lenvatinib. | |
|
V79962 | Multi-kinase-IN-5 | Multi-kinase-IN-5 (compound 15c) is a promising multi-kinase inhibitor. | |
|
V2671 | NSC-12 | 102586-30-1 | NSC-12 (also known as NSC12; NSC 172285) is an orally available pan-FGF trap able to inhibit FGF2/FGFR interaction and endowed with promising antitumor activity. |
|
V26847 | ODM-203 | 1430723-35-5 | ODM-203 is a potent and orally bioavailable inhibitor of FGFRandVEGFRfamilies inhibitor withIC50s of 11, 16, 6, 35 nM towards recombinant FGFR1, FGFR2, FGFR3 and FGFR4 as well as 26, 9, 5 nM towards VEGFR1, VEGFR2 and VEGFR3, respectively. |
|
V2723 | PD166866 | 192705-79-6 | PD166866, a member of a new structural class of tyrosine kinase inhibitors, the 6-aryl-pyrido[2,3-d]pyrimidines, is a a new nanomolar potent and selective small molecule inhibitor of FGFR (fibroblast growth factor-1 receptor) tyrosine kinase inhibitor with an IC50 of 52.4 nM. |
|
V34674 | Pemigatinib (INCB054828) | 1513857-77-6 | Pemigatinib (formerly INCB054828; INCB-054828; Pemazyre) is a novel, potent, orally bioavailable and selective FGFR inhibitor with IC50 of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively. |
|
V2780 | PRN1371 | 1802929-43-6 | PRN1371 is a highly selective, potent, covalent, and irreversible FGFR1,2,3,4 inhibitor with IC50 values of 0.6, 1.3, 4.1 and 19.3 nM, respectively. |
|
V69482 | Recifercept (TA-46; sFGFR3) | 2226238-09-9 | Recifercept (TA-46) is a soluble recombinant fibroblast growth factor receptor 3 (FGFR3) molecule. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
